These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 14996699)

  • 21. Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis.
    Onorato L; Macera M; Calò F; Cirillo P; Di Caprio G; Coppola N
    Int J Antimicrob Agents; 2022 Mar; 59(3):106512. PubMed ID: 34971728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.
    Vardakas KZ; Voulgaris GL; Maliaros A; Samonis G; Falagas ME
    Lancet Infect Dis; 2018 Jan; 18(1):108-120. PubMed ID: 29102324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.
    Roberts JA; Abdul-Aziz MH; Davis JS; Dulhunty JM; Cotta MO; Myburgh J; Bellomo R; Lipman J
    Am J Respir Crit Care Med; 2016 Sep; 194(6):681-91. PubMed ID: 26974879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?
    Ong DSY; van Werkhoven CH; Cremer OL; Thwaites GE; Bonten MJM
    Clin Microbiol Infect; 2018 Feb; 24(2):95-96. PubMed ID: 28989114
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.
    Bliziotis IA; Petrosillo N; Michalopoulos A; Samonis G; Falagas ME
    PLoS One; 2011; 6(10):e26470. PubMed ID: 22046290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis.
    Elphick HE; Tan A
    Cochrane Database Syst Rev; 2001; (1):CD002007. PubMed ID: 11279745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
    Paul M; Yahav D; Fraser A; Leibovici L
    J Antimicrob Chemother; 2006 Feb; 57(2):176-89. PubMed ID: 16344285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there evidence on the optimal duration of aminoglycoside therapy in β-lactam/aminoglycoside combination regimens used for the treatment of gram-negative bacterial infections? A systematic review.
    Wale YM; Roberts JA; Wolie ZT; Sime FB
    Int J Antimicrob Agents; 2024 Oct; 64(4):107297. PubMed ID: 39111709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aminoglycosides versus beta-lactams in gram-negative pneumonia.
    Collins T; Gerding DN
    Semin Respir Infect; 1991 Sep; 6(3):136-46. PubMed ID: 1754734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study).
    Albasanz-Puig A; Gudiol C; Puerta-Alcalde P; Ayaz CM; Machado M; Herrera F; Martín-Dávila P; Laporte-Amargós J; Cardozo C; Akova M; Álvarez-Uría A; Torres D; Fortún J; García-Vidal C; Muñoz P; Bergas A; Pomares H; Mercadal S; Durà-Miralles X; García-Lerma E; Pallarès N; Carratalà J
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0004521. PubMed ID: 33972253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms.
    Martínez JA; Cobos-Trigueros N; Soriano A; Almela M; Ortega M; Marco F; Pitart C; Sterzik H; Lopez J; Mensa J
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3590-6. PubMed ID: 20585123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A comparative review of combination therapy: 2 beta-lactams versus beta-lactam plus aminoglycoside].
    Dejace P; Klastersky J
    Infection; 1987; 15 Suppl 4():S158-67. PubMed ID: 3312028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the addition of aminoglycosides to beta-lactams in cancer patients with febrile neutropenia needed?
    Contreras V; Sepúlveda S; Heredia A
    Medwave; 2016 Feb; 16 Suppl 1():e6379. PubMed ID: 26938974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic Review of Beta-Lactam vs. Beta-Lactam plus Aminoglycoside Combination Therapy in Neutropenic Cancer Patients.
    Ishikawa K; Nakamura T; Kawai F; Ota E; Mori N
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
    An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
    Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
    Mills GD; Oehley MR; Arrol B
    BMJ; 2005 Feb; 330(7489):456. PubMed ID: 15684024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aminoglycosides are useful for severe respiratory tract infections.
    Craig WA; Andes D
    Semin Respir Infect; 1997 Dec; 12(4):271-7. PubMed ID: 9436954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is double coverage of gram-negative organisms necessary?
    Johnson SJ; Ernst EJ; Moores KG
    Am J Health Syst Pharm; 2011 Jan; 68(2):119-24. PubMed ID: 21200057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit?
    Rahme C; Butterfield JM; Nicasio AM; Lodise TP
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):239-59. PubMed ID: 25308565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empiric combination therapy for gram-negative bacteremia.
    Sick AC; Tschudin-Sutter S; Turnbull AE; Weissman SJ; Tamma PD
    Pediatrics; 2014 May; 133(5):e1148-55. PubMed ID: 24709936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.